Joseph Tucker, CEO and director at Enveric Biosciences, a biotech firm, suggested a pair of obstacles this study simply couldn’t overcome. “The thematic challenges that came to light in the Lykos [trial] largely focused around two elements: expectation bias and the delivery of the psychological therapy,” Tucker argued. “These are difficult to separate from any therapy that induces hallucinations and/or requires psychotherapy in the treatment protocol but would likely be eliminated as concerns for the impending next generation of non-hallucinogenic neuroplastogens.”
